Showing 491-500 of 834 results for "".
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- Phase 3 Stage 1 DIAMOND Trial Results of Oculis' OCS-01 in DME Presented at Euretinahttps://modernod.com/news/phase-3-stage-1-diamond-trial-results-of-oculis-ocs-01-in-dme-presented-euretina/2481877/Oculis announced that Professor Ramin Tadayoni, MD, PhD, presented the positive results from stage 1 of the phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress in Amsterdam. The data showed that the trial met primary and secondary endpoints
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb
- Pioneers in Retinal Gene Therapies Awarded International Harrington Prizehttps://modernod.com/news/pioneers-in-retinal-gene-therapies-awarded-international-harrington-prize/2481453/The tenth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Jean Bennett, MD, PhD, the F.M. Kirby Emeritus Professor of Ophthalmology and Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania;
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Eyenovia Announces Changes to Board of Directorshttps://modernod.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/Eyenovia announced changes to its Board of Directors. Sean Ianchulev, MD, PhD, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director